Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Bevacizumab Does Not Impact Overall Survival, Quality of Life

A new report indicates that the use of bevacizumab (Avastin) in the treatment of women with metastatic breast cancer slows the progression of the disease but has no impact on their overall survival, the length of time women live after receiving treatment, or on their quality of life.

Good Dental Hygiene May Help Prevent Osteonecrosis

New evidence suggests that osteonecrosis of the jaw is uncommon after treatment with bisphosphonates or denosumab (Xgeva), a lab-created protein used to prevent bone fractures in cancers that metastasized to the bone. Monitoring oral dental health may prevent or resolve osteonecrosis as a side effect, the study found.

T-DM1 Delays Time to Progression and Extends Survival

Results from the international EMILIA study suggest a new effective treatment for HER2 positive metastatic breast cancer, using trastuzumab (Herceptin) linked with the potent chemotherapy DM1.

Everolimus Gains FDA Approval for Metastatic Breast Cancer

Postmenopausal women with metastatic, hormone receptor-positive breast cancer may now be treated with everolimus (Afinitor) in combination with exemestane (Aromasin), following FDA’s recent approval of the tablet medicine.

FDA Approves Perjeta for Metastatic Breast Cancer

FDA approves pertuzumab (Perjeta) for use in treating HER2 positive metastatic breast cancer when combined with trastuzumab (Herceptin), an anti-HER2 medicine that targets a different part of the HER2 protein, and docetaxel (Taxotere), a type ofchemotherapy.

Breast cancer cells can turn off key immune response: study

HONG KONG (Reuters) - Breast cancer cells can shut down a powerful immune response in the body, which allows the disease to spread to the patient's bones, researchers in Australia reported on Monday.

FDA approves Novartis drug Afinitor for breast cancer

(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Novartis AG's drug Afinitor to treat women with a certain type of breast cancer.

Costly newer drugs no better in breast cancer study

(Reuters) - A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study.

Drug delays spread of certain breast cancers

CHICAGO (Reuters) - A study of Roche's experimental "armed antibody" found it extended the length of time breast cancer patients lived without their disease getting worse, marking the second successful pivotal trial in this new class of cancer drugs.

Celldex breast cancer drug shrinks some tumors-study

(Reuters) - Interim results from a mid-stage trial of Celldex Therapeutics Inc's experimental drug showed trends toward reducing tumors in patients with advanced breast cancer, with rates improving for those patients with high levels of a key protein.

Denver, CO  ·  September 13, 2014

Join Your Community for Yoga on the Steps!

Close
close